Mark A.  Emalfarb net worth and biography

Mark Emalfarb Biography and Net Worth

Mark A. Emalfarb is the founder of Dyadic. He has been a member of Dyadic’s board of directors since October 2004 and has served as its Chairman as well as President and Chief Executive Officer from October 2004 until April 2007 and from June 2008 until the present.

Since founding Dyadic in 1979, Mr. Emalfarb has successfully led and managed the evolution of Dyadic from its origins as a pioneer and leader in providing ingredients used in the stone-washing of blue jeans to the discovery, development, manufacturing and commercialization of specialty enzymes used in various industrial applications and the development of an integrated technology platform based on Dyadic’s patented and proprietary C1 fungal microorganism.

Mr. Emalfarb is an inventor of over 25 U.S. and foreign biotechnology patents and patent applications resulting from discoveries related to the Company’s patented and proprietary C1 fungus, and has been the architect behind its formation of several strategic research and development, manufacturing and marketing relationships with U.S. and international partners.

Mr. Emalfarb earned his B.A. degree from the University of Iowa in 1977.

How old is Mark A. Emalfarb?

Mr. Emalfarb is currently 68 years old. There are 1 older executives and no younger executives at Dyadic International. Learn More on Mark A. Emalfarb's age.

How do I contact Mark A. Emalfarb?

The corporate mailing address for Mr. Emalfarb and other Dyadic International executives is 140 INTRACOASTAL POINTE DRIVE SUITE 404, JUPITER FL, 33477. Dyadic International can also be reached via phone at (561) 743-8333 and via email at [email protected]. Learn More on Mark A. Emalfarb's contact information.

Has Mark A. Emalfarb been buying or selling shares of Dyadic International?

Mark A. Emalfarb has not been actively trading shares of Dyadic International in the last ninety days. Most recently, Mark A. Emalfarb sold 28,767 shares of the business's stock in a transaction on Thursday, December 23rd. The shares were sold at an average price of $4.10, for a transaction totalling $117,944.70. Learn More on Mark A. Emalfarb's trading history.

Who are Dyadic International's active insiders?

Dyadic International's insider roster includes Mark Emalfarb (CEO), and Ping Rawson (CFO). Learn More on Dyadic International's active insiders.

Mark A. Emalfarb Insider Trading History at Dyadic International

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/23/2021Sell28,767$4.10$117,944.70View SEC Filing Icon  
12/21/2021Sell26,486$4.33$114,684.38View SEC Filing Icon  
6/9/2021Sell23,000$3.72$85,560.00View SEC Filing Icon  
6/7/2021Sell44,000$3.95$173,800.00View SEC Filing Icon  
6/4/2021Sell132,000$3.85$508,200.00View SEC Filing Icon  
6/2/2021Sell76,349$3.74$285,545.26View SEC Filing Icon  
See Full Table

Mark A. Emalfarb Buying and Selling Activity at Dyadic International

This chart shows Mark A Emalfarb's buying and selling at Dyadic International by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dyadic International Company Overview

Dyadic International logo
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design,Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida.
Read More

Today's Range

Now: $1.63
Low: $1.58
High: $1.65

50 Day Range

MA: $1.44
Low: $1.29
High: $1.67

2 Week Range

Now: $1.63
Low: $1.19
High: $2.40

Volume

7,612 shs

Average Volume

21,810 shs

Market Capitalization

$46.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58